Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC

(4503)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Astellas Pharma : buys Potenza Therapeutics for up to $405m

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/18/2018 | 03:50am EDT

Japanese pharmaceutical company Astellas Pharma has acquired US-based Potenza Therapeutics for a total consideration of up to $405m.

The deal is made possible as Astellas exercised its option to buy Potenza Therapeutics under a collaboration agreement signed in 2015 for the development of new immuno-oncology (IO) therapies.

Astellas made an upfront payment of $164.6m; Potenza will be eligible for additional payment of up to $240.1m dependent on the progress of different programmes in clinical development.

Following the completion of the transaction, Potenza has become a wholly-owned subsidiary of Astellas.

Astellas Pharma president and CEO Kenji Yasukawa said: In oncology, Astellas has focused on developing treatments for unmet medical needs with novel mechanisms of action and modalities.

We believe the novel assets we have developed with Potenza have the potential to make an even more pronounced difference for patients in need.

Over their alliance period, Astellas and Potenza discovered and developed three investigational new drugs (INDs) ASP8374/PTZ-201, ASP1948/PTZ-329 and ASP1951/PTZ-522.

The drug candidates are said to have the potential to treat a variety of cancers non-responsive or resistant to the current generation of IO therapies.

ASP8374/PTZ-201 is an immune checkpoint inhibitor, while ASP1948/PTZ-329 inhibits Treg function. Both the compounds are undergoing Phase I clinical trials.

ASP1951/PTZ-522 is a GITR agonistic antibody that holds investigational new drug clearance.

Potenza Therapeutics president and CEO Dan Hicklin said: Over the past three and a half years, we have enjoyed a successful and productive partnership with Astellas.

I am pleased that these therapies will now have access to the resources of a large international company, with world-class R&D and the strategic and financial backing to support the development of these innovative potential new medicines for cancer patients in need.

The clinical IO therapies resulting from the partnership are expected to enable combinations with Astellas existing non-IO programmes for life cycle management and future IO combinations.

(c) 2018 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
07/17SEATTLE GENETICS : and Astellas Announce Submission of Biologics License Applica..
AQ
07/16ASTELLAS PHARMA : and Seattle Genetics Announce Submission of Biologics License ..
PU
07/09ASTELLAS PHARMA : Launch of Smyraf® Tablets - Provides a new therapeutic option ..
PU
06/26ASTELLAS PHARMA : Named to FTSE4Good Index Series for the Eighth Consecutive Yea..
PU
06/18ASTELLAS PHARMA : Hypercholesterolemia drug repatha® sc injection receives suppl..
PU
06/11ASTELLAS PHARMA : Otsuka enters the API business after Astellas asset acquisitio..
AQ
06/04SEATTLE GENETICS : and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedo..
AQ
06/03ASTELLAS PHARMA : and Seattle Genetics Announce Antibody-Drug Conjugate Enfortum..
PU
05/31ASTELLAS PHARMA INC. : - U.S. FDA Approves Supplemental New Drug Application Add..
AQ
05/27ASTELLAS PHARMA INC : Mixed general shareholder meeting
CO
More news
Financials (JPY)
Sales 2020 1 237 B
EBIT 2020 237 B
Net income 2020 189 B
Finance 2020 419 B
Yield 2020 2,64%
P/E ratio 2020 15,2x
P/E ratio 2021 14,1x
EV / Sales2020 2,02x
EV / Sales2021 1,90x
Capitalization 2 917 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 1 933,00  JPY
Last Close Price 1 547,00  JPY
Spread / Highest target 61,6%
Spread / Average Target 25,0%
Spread / Lowest Target -19,2%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda General Manager-Pharmaceutical Technology
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC13.14%27 354
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273